Leukemia clinical trials in Arizona

32 actively recruiting leukemia trials at 10 sites across Arizona.

Data from ClinicalTrials.gov · last refreshed 2026-06-15

Payments from drug makers to the doctors running these trials

For 2 of the trials on this page, the pharmaceutical company funding the trial also disclosed payments to the physicians leading it — public data from the federal CMS Open Payments database. Paying clinical-trial investigators for site work is expected and necessary for industry-funded trials; the scale and source are simply useful context when you're deciding whether to enroll. See the full leukemia transparency page →

Payments from the drug maker running this trial to its lead doctors

CMS Open Payments · 2024

AbbVie funds and runs this clinical trial (NCT06428019). In 2024, AbbVie reported paying the doctors leading the trial a total of $247,582 for research work on this study.

Who paid

ABBVIE INC. $247,582

Paid for research work on this trial

FARRUKH AWAN(oncologist on CancerDrs) $53,750
BRUCE CHESON(oncologist on CancerDrs) $51,969
ARI PELCOVITS $33,090
PREET SINGH(oncologist on CancerDrs) $32,190
SHALIN KOTHARI(oncologist on CancerDrs) $24,500

Questions a patient might reasonably ask

Who is funding this trial, and how does the funding company stand to benefit if the trial succeeds?
Does my oncologist have a financial relationship with the trial sponsor outside of this trial?
Are there non-industry-sponsored trials (NIH, cooperative group) for my condition I should consider?
What are the alternative standards of care I should compare against enrolling here?

Research payments are not, by themselves, a conflict — paying for legitimate trial work is how drug development gets funded. The purpose of Sunshine Act disclosure is to give patients the context, not to make the decision for them.

Source: CMS Open Payments · ClinicalTrials.gov · Dispute process · How we compute this

As displayed on 2026-04-21. Corrections flow from the manufacturer through CMS and are adopted on our next refresh.

Payments from the drug maker running this trial to its lead doctors

CMS Open Payments · 2024

Loxo Oncology, Inc. funds and runs this clinical trial (NCT06588478). In 2024, Loxo Oncology, Inc. reported paying the doctors leading the trial a total of $137,646 for research work on this study.

Who paid

Eli Lilly and Company $137,646

Paid for research work on this trial

JAMES D'OLIMPIO(oncologist on CancerDrs) $127,194
BITA FAKHRI(oncologist on CancerDrs) $1,307
BRUCE CHESON(oncologist on CancerDrs) $1,307
JACKSON GAO(oncologist on CancerDrs) $1,307
TARA GRAFF(oncologist on CancerDrs) $1,307

Questions a patient might reasonably ask

Who is funding this trial, and how does the funding company stand to benefit if the trial succeeds?
Does my oncologist have a financial relationship with the trial sponsor outside of this trial?
Are there non-industry-sponsored trials (NIH, cooperative group) for my condition I should consider?
What are the alternative standards of care I should compare against enrolling here?

Source: CMS Open Payments · ClinicalTrials.gov · Dispute process · How we compute this

As displayed on 2026-04-21. Corrections flow from the manufacturer through CMS and are adopted on our next refresh.

Phase 3 Recruiting Academic/Other

Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia

This partially randomized phase III trial studies the side effects of inotuzumab ozogamicin and how well it works when given with frontline chemotherapy in treating patients with newly diagnosed B acute lymphoblastic leukemia. Monoclonal a…

Sponsor: Alliance for Clinical Trials in Oncology

NCT ID: NCT03150693

Sites in Arizona:

Kingman Regional Medical Center — Kingman, Arizona
Mayo Clinic Hospital in Arizona — Phoenix, Arizona
Mayo Clinic in Arizona — Scottsdale, Arizona